Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Avvisati

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
La Clinica Terapeutica|May 3, 2005
[Primary lymphoma of the serous body cavities]G Avvisati
La Clinica Terapeutica|April 20, 2002
[Hematologic etiology of thromboembolic disease]G Avvisati
Hematology/Oncology Clinics of North America|April 1, 1992
The role of interferon-alpha in the management of myelomatosisG Avvisati, F Mandelli
Stem Cells (Dayton, Ohio)|August 1, 1995
Is alpha-interferon treatment in multiple myeloma worthwhile?G Avvisati, M T Petrucci
Current Opinion in Oncology|February 1, 1992
Biology and treatment of multiple myelomaF Mandelli, G Avvisati, M Tribalto
Bailliere'S Clinical Haematology|March 1, 1994
The interferons in haematological malignanciesF Mandelli, W Arcese, G Avvisati
Advances in Hematology|December 23, 2011
Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic LeukemiaF Marchesi, K Girardi, G Avvisati
European Journal of Haematology. Supplementum|January 1, 1989
Interferon: a new strategy in the treatment of multiple myelomaF Mandelli, G Avvisati, M T Petrucci
Seminars in Hematology|February 15, 2001
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factorsG Avvisati, F Lo Coco, F Mandelli
Leukemia & Lymphoma|January 1, 1993
What is the best treatment for acute promyelocytic leukemia?G Avvisati, M C Petti, F Mandelli
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
La Clinica Terapeutica|May 3, 2005
[Primary lymphoma of the serous body cavities]G Avvisati
La Clinica Terapeutica|April 20, 2002
[Hematologic etiology of thromboembolic disease]G Avvisati
Hematology/Oncology Clinics of North America|April 1, 1992
The role of interferon-alpha in the management of myelomatosisG Avvisati, F Mandelli
Stem Cells (Dayton, Ohio)|August 1, 1995
Is alpha-interferon treatment in multiple myeloma worthwhile?G Avvisati, M T Petrucci
Current Opinion in Oncology|February 1, 1992
Biology and treatment of multiple myelomaF Mandelli, G Avvisati, M Tribalto
Bailliere'S Clinical Haematology|March 1, 1994
The interferons in haematological malignanciesF Mandelli, W Arcese, G Avvisati
Advances in Hematology|December 23, 2011
Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic LeukemiaF Marchesi, K Girardi, G Avvisati
European Journal of Haematology. Supplementum|January 1, 1989
Interferon: a new strategy in the treatment of multiple myelomaF Mandelli, G Avvisati, M T Petrucci
Seminars in Hematology|February 15, 2001
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factorsG Avvisati, F Lo Coco, F Mandelli
Leukemia & Lymphoma|January 1, 1993
What is the best treatment for acute promyelocytic leukemia?G Avvisati, M C Petti, F Mandelli
Pageof 15